

Triflusal

Catalog No: tcsc2755



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

322-79-2

Formula:

$C_{10}H_7F_3O_4$

Pathway:

Immunology/Inflammation

Target:

COX

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

248.16


Product Description

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cyclooxygenase-1.

Target: COX

Triflusal at 10 mM, 100 mM and 1 M decreases LDH efflux in rat brain slices after anoxia/reoxygenation by 24%, 35% and 49% respectively. Triflusal also reduces inducible NO synthase activity by 18%, 21% and 30% [1].

Triflusal (10 mg/kg i.v.) reduces platelet deposition on subendothelium-induced primary thrombus by about 68% in rabbits. Triflusal (10 mg/kg i.v.) reduces platelet deposition on a fresh thrombus formed over tunica media by about 48% in rabbits. Triflusal (40 mg/kg p.o.) reduces platelet deposition on a primary thrombus triggered by subendothelium and tunica media by 53% in rabbits. Triflusal (40 mg/kg p.o.) significantly reduces Cox-2 mRNA levels and protein levels without influence Cox-1 mRNA levels on the vascular wall in rabbits [2]. Triflusal (600 mg/day for 5 days) results in an increase in NO production by neutrophils and an increase in endothelial nitric oxide synthase (eNOS) protein expression in neutrophils in healthy volunteers [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!